Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Thermo Fisher (TMO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Thermo Fisher Scientific Inc.'s stock TMO, -7.80% fell about 9% Wednesday to put it on track for its lowest close in more than three years, after the supplier of analytics, diagnostics and laboratory services missed revenue estimates for its third quarter and trimmed guidance. The company posted net income of $1.715 billion, or $4.42 a share, for the quarter, up from $1.495 billion, or $3.79 a share, in the year-earlier period.

Thermo Fisher's stock on track for lowest close in more than three years after revenue miss and lowered guidance

Thermo Fisher Scientific (NYSE:TMO) issued a forecast for full-year profit and sales that falls below Wall Street expectations on lower-than-expected demand for its services used in the production of therapies and vaccines, as well as increased costs for raw materials. It is the second consecutive quarter in which the company has reduced its annual adjusted profit expectations.

Thermo Fisher lowers profit and sales outlook on soft demand, rising costs

Thermo Fisher Scientific cut its full-year guidance for the second time this year on Wednesday, and TMO stock took a hit.

Thermo Fisher Slumps After Medical Behemoth Cuts Its 2023 Outlook — Again

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.69 per share, beating the Zacks Consensus Estimate of $5.58 per share. This compares to earnings of $5.08 per share a year ago.

Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates

The leading maker of scientific equipment slashes its guidance for the second consecutive quarter, citing a challenging macro environment.

Thermo Fisher Stock Slumps After Sales Miss and Outlook Is Slashed Again

Medical equipment maker Thermo Fisher Scientific on Wednesday cut its annual profit forecast for the second straight quarter, hurt by lower-than-expected demand for its services used to make therapeutics, vaccines and analytical tools.

Thermo Fisher cuts annual profit forecast on weak biotech demand

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights Third quarter revenue was $10.57 billion, 1% lower versus the same quarter last year. Core organic revenue growth was 1%. Third quarter GAAP diluted earnings per share (EPS) was $4.42, 17% higher versus the same quarter last year, driven by 160 basis points of operating.

Thermo Fisher Scientific Reports Third Quarter 2023 Results

Avantor Inc.

Catalent

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Repligen

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

CARLSBAD, Calif.--(BUSINESS WIRE)--To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments, Thermo Fisher Scientific today announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim. Through this collaboration, the companies will work to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations. Lung ca.

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Boehringer Ingelheim to Select Patients with NSCLC for Targeted Therapy Treatment

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Olink Holding AB

Olink Holding AB shares surged 66% to $24.87 in late-morning trading on Tuesday after the provider of next-generation proteomics solutions announced that it has agreed to be acquired by Thermo Fisher Scientific (NYSE:TMO) Inc for $26 per share in cash, representing a premium of about 74% to the closing price of Olink's Nasdaq-listed American Depositary Shares (ADS) on October 16, 2023.  The transaction values Olink at approximately $3.1 billion, which includes net cash of about $143 million.

Olink Holding stock soars on acquisition by Thermo Fisher Scientific

Thermo Fisher Scientific plans to acquire Olink for $3.1 billion. The deal would add Olink's proteomics technology to Thermo Fisher's life sciences solutions.

Why Olink Stock Is Skyrocketing Today

Thermo Fisher will acquire proteomics company Olink for $26 per American depositary share in cash.

Thermo Fisher to Buy Sweden's Olink for $3.1 Billion

Thermo Fisher Scientific Inc. TMO, +1.18% announced Tuesday an agreement to buy Sweden-based proteomics company Olink Holding AB OLK, +0.47% in a deal that values Olink at about $3.1 billion, including $143 million in cash. Olink's stock was halted for news until 8:50 a.m.

Thermo Fisher's stock slips after deal to buy Sweden's Olink for a 74% premium

WALTHAM, Mass. & UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. This represents a pre.

Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics

Charles River Laboratories

SAN FRANCISCO--(BUSINESS WIRE)-- #manufacturing--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs (including but not limited to cell therapies), announced today that its proof-of-concept robotic system, developed along with UCSF, Cytiva, Thermo Fisher Scientific and Charles River, has been successfully completed. The data from this project indicate that manual cell therapy manufacturing tasks (and in particular, cell expansion processe.

Multiply Labs Collaborates with Industry Leaders University of California San Francisco, Cytiva, Thermo Fisher Scientific and Charles River to Deliver a Successful Proof-of-Concept of Robotic Cell Therapy Manufacturing

Thermo Fisher (TMO) is registering strong growth in the electron microscopy and chromatography and mass spectrometry businesses in the academic and government end market.

Thermo Fisher's (TMO) Strong End Markets and New Buyouts Aid

The latest trading day saw Thermo Fisher Scientific (TMO) settling at $498.55, representing a +0.11% change from its previous close.

Thermo Fisher Scientific (TMO) Increases Yet Falls Behind Market: What Investors Need to Know

Thermo Fisher (TMO) expands manufacturing capacity at the St. Louis site for Biologics treatment.

Thermo Fisher (TMO) Expands Capabilities in St. Louis Facility

Thermo Fisher Scientific (TMO) closed at $498.02 in the latest trading session, marking a -0.88% move from the prior day.

Thermo Fisher Scientific (TMO) Sees a More Significant Dip Than Broader Market: Some Facts to Know

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders. Thermo Fisher made a significant investment since 2021 to add 58,000 square feet of biologics manufacturing space. The addition was facilitated by state and local tax incentives, including a 10-year new project abatement beginning.

Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2023 before the market opens on Wednesday, October 25, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. T.

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 25, 2023

Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.

News for Thermo Fisher Scientific Stock (TMO)